589 related articles for article (PubMed ID: 17062778)
41. Product inhibition of UDP-glucuronosyltransferase (UGT) enzymes by UDP obfuscates the inhibitory effects of UGT substrates.
Fujiwara R; Nakajima M; Yamanaka H; Katoh M; Yokoi T
Drug Metab Dispos; 2008 Feb; 36(2):361-7. PubMed ID: 17998297
[TBL] [Abstract][Full Text] [Related]
42. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies.
Wang L; Zhang D; Raghavan N; Yao M; Ma L; Frost CE; Maxwell BD; Chen SY; He K; Goosen TC; Humphreys WG; Grossman SJ
Drug Metab Dispos; 2010 Mar; 38(3):448-58. PubMed ID: 19940026
[TBL] [Abstract][Full Text] [Related]
43. In vitro metabolism of rivoglitazone, a novel peroxisome proliferator-activated receptor γ agonist, in rat, monkey, and human liver microsomes and freshly isolated hepatocytes.
Uchiyama M; Koda H; Fischer T; Mueller J; Yamamura N; Oguchi M; Iwabuchi H; Okazaki O; Izumi T
Drug Metab Dispos; 2011 Jul; 39(7):1311-9. PubMed ID: 21511943
[TBL] [Abstract][Full Text] [Related]
44. Oxidation of the novel oxazolidinone antibiotic linezolid in human liver microsomes.
Wynalda MA; Hauer MJ; Wienkers LC
Drug Metab Dispos; 2000 Sep; 28(9):1014-7. PubMed ID: 10950842
[TBL] [Abstract][Full Text] [Related]
45. Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4.
Störmer E; von Moltke LL; Shader RI; Greenblatt DJ
Drug Metab Dispos; 2000 Oct; 28(10):1168-75. PubMed ID: 10997935
[TBL] [Abstract][Full Text] [Related]
46. Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes.
Kilford PJ; Stringer R; Sohal B; Houston JB; Galetin A
Drug Metab Dispos; 2009 Jan; 37(1):82-9. PubMed ID: 18832476
[TBL] [Abstract][Full Text] [Related]
47. In Vitro Inhibitory Effects of Synthetic Cannabinoid EAM-2201 on Cytochrome P450 and UDP-Glucuronosyltransferase Enzyme Activities in Human Liver Microsomes.
Kong TY; Kwon SS; Cheong JC; Kim HS; Kim JY; Lee HS
Molecules; 2018 Apr; 23(4):. PubMed ID: 29659506
[TBL] [Abstract][Full Text] [Related]
48. Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells.
Westerink WM; Schoonen WG
Toxicol In Vitro; 2007 Dec; 21(8):1581-91. PubMed ID: 17637504
[TBL] [Abstract][Full Text] [Related]
49. Characterization of human liver cytochrome P450 enzymes involved in the metabolism of a new H+/K+-ATPase inhibitor KR-60436.
Ji HY; Lee HW; Kim HH; Choi JK; Lee HS
Toxicol Lett; 2005 Jan; 155(1):103-14. PubMed ID: 15585365
[TBL] [Abstract][Full Text] [Related]
50. Characterization of human cytochrome P450 enzymes involved in the in vitro metabolism of perospirone.
Kitamura A; Mizuno Y; Natsui K; Yabuki M; Komuro S; Kanamaru H
Biopharm Drug Dispos; 2005 Mar; 26(2):59-65. PubMed ID: 15619261
[TBL] [Abstract][Full Text] [Related]
51. In vitro identification of the P450 enzymes responsible for the metabolism of ropinirole.
Bloomer JC; Clarke SE; Chenery RJ
Drug Metab Dispos; 1997 Jul; 25(7):840-4. PubMed ID: 9224778
[TBL] [Abstract][Full Text] [Related]
52. In vitro characterisation of human renal and hepatic frusemide glucuronidation and identification of the UDP-glucuronosyltransferase enzymes involved in this pathway.
Kerdpin O; Knights KM; Elliot DJ; Miners JO
Biochem Pharmacol; 2008 Jul; 76(2):249-57. PubMed ID: 18541222
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of the selectivity of In vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities.
Hickman D; Wang JP; Wang Y; Unadkat JD
Drug Metab Dispos; 1998 Mar; 26(3):207-15. PubMed ID: 9492382
[TBL] [Abstract][Full Text] [Related]
54. Human hepatic cytochrome p450-specific metabolism of parathion and chlorpyrifos.
Foxenberg RJ; McGarrigle BP; Knaak JB; Kostyniak PJ; Olson JR
Drug Metab Dispos; 2007 Feb; 35(2):189-93. PubMed ID: 17079358
[TBL] [Abstract][Full Text] [Related]
55. Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes.
Chauret N; Gauthier A; Nicoll-Griffith DA
Drug Metab Dispos; 1998 Jan; 26(1):1-4. PubMed ID: 9443844
[TBL] [Abstract][Full Text] [Related]
56. Metabolism of dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylene dioxybiphenyl-2,2'-dicarboxylate (DDB) by human liver microsomes: characterization of metabolic pathways and of cytochrome P450 isoforms involved.
Baek MS; Kim JY; Myung SW; Yim YH; Jeong JH; Kim DH
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):381-8. PubMed ID: 11259320
[TBL] [Abstract][Full Text] [Related]
57. Oxidative metabolism of lansoprazole by human liver cytochromes P450.
Pichard L; Curi-Pedrosa R; Bonfils C; Jacqz-Aigrain E; Domergue J; Joyeux H; Cosme J; Guengerich FP; Maurel P
Mol Pharmacol; 1995 Feb; 47(2):410-8. PubMed ID: 7870052
[TBL] [Abstract][Full Text] [Related]
58. In vitro metabolism study of buprenorphine: evidence for new metabolic pathways.
Picard N; Cresteil T; Djebli N; Marquet P
Drug Metab Dispos; 2005 May; 33(5):689-95. PubMed ID: 15743975
[TBL] [Abstract][Full Text] [Related]
59. Involvement of human CYP1A isoenzymes in the metabolism and drug interactions of riluzole in vitro.
Sanderink GJ; Bournique B; Stevens J; Petry M; Martinet M
J Pharmacol Exp Ther; 1997 Sep; 282(3):1465-72. PubMed ID: 9316860
[TBL] [Abstract][Full Text] [Related]
60. Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate.
Venkatakrishnan K; von Moltke LL; Greenblatt DJ
J Pharmacol Exp Ther; 2001 Apr; 297(1):326-37. PubMed ID: 11259560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
